
-20C

Store at

2048

#1





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	<b>Reactivity:</b> H	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 17,19, 30	<b>Source/Isotype:</b> Rabbit IgG	<b>UniProt ID:</b> #O14944	Entrez-Gene Id: 2069		
Product Usage Information	2	<b>Application</b> Western Blotting Immunoprecipitation			<b>Dilution</b> 1:1000 1:100			
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
Specificity/Ser	<b>Decificity/Sensitivity</b> EREG (D4O5I) Rabbit mAb recognizes endogenous levels of proepiregulin and the C-terminal propeptide of the EREG protein. It does not recognize the mature form of EREG.				terminal			
Source / Purifi	cation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu155 of human EREG protein.						
Background		Epiregulin (EREG) belongs to the epidermal growth factor (EGF) family and is a ligand for the EGF receptor (EGFR) and ErbB4 (1-3). The binding of EREG to homodimers, as well as heterodimers containing EGFR or ErbB4, leads to receptor activation and downstream signaling to promote cell growth and proliferation (4-6). In normal human tissue, moderate levels of EREG are expressed in the placenta and peripheral blood macrophages. Research studies have shown that EREG is expressed at high levels in numerous cancer cell lines, and EREG expression is correlated with primary cancer aggresiveness/metastases (7-11). In addition to its involvement in tumorigenesis, a variant of EREG has also been shown to be associated with tuberculosis susceptibility (12). EREG is synthesized as a ~30 kDa glycosylated membrane bound proepiregulin form (19 kDa when not glycosylated) and through subsequent proteolytic cleavage is processed to a 17 kDa C-terminal propeptide, and the 6kDa mature form of epiregulin (13).						
Background R	eferences	<ol> <li>Olayioye, M.A. et al. (2000) <i>EMBO J</i> 19, 3159-67.</li> <li>Shelly, M. et al. (1998) <i>J Biol Chem</i> 273, 10496-505.</li> <li>Komurasaki, T. et al. (1997) <i>Oncogene</i> 15, 2841-8.</li> <li>Komurasaki, T. et al. (2002) <i>Growth Factors</i> 20, 61-9.</li> <li>Shirakata, Y. et al. (2000) <i>J Biol Chem</i> 275, 5748-53.</li> <li>Toyoda, H. et al. (1995) <i>J Biol Chem</i> 270, 7495-500.</li> <li>Toyoda, H. et al. (1997) <i>Biochem J</i> 326 ( Pt 1), 69-75.</li> <li>Zhu, Z. et al. (2000) <i>Biochem Biophys Res Commun</i> 273, 1019-24.</li> <li>Kuramochi, H. et al. (2012) <i>BMC Cancer</i> 12, 88.</li> <li>Zhang, J. et al. (2008) <i>Cancer Prev Res (Phila)</i> 1, 201-7.</li> <li>Sunaga, N. et al. (2012) <i>Genes Immun</i> 13, 275-81.</li> <li>Baba, I. et al. (2000) <i>Cancer Res</i> 60, 6886-9.</li> </ol>						
Species Reacti	vity	Species reactivity is det	ermined by testing	g in at least one approve	ed application (e.g.,	western blot).		
Western Blot B	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications K	ley	W: Western Blotting IP: Immunoprecipitation						
Cross-Reactivi	ty Key	H: Human						
<b>Trademarks and Patents</b> Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				logy, Inc.				
		All other trademarks ar more information.	re the property of t	heir respective owners.	Visit cellsignal.com	/trademarks for		

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.